dr. A.M.E. (Annelies) Bos
Associate Professor - medical
- Reproductive Medicine & Gynecology - Medical
Contact
Biography
Doctorate 5th of March, 2003
Thesis: Optimizing conventional chemotherapy approaches. Studies on feasibility and pharmacokinetics.
Promotores: Prof. dr. E.G.E. de Vries and Prof. dr. A.G.J. van der Zee, co-promotor: Dr. P.H.B. Willemse
Department Medical Oncology/Gynaecology-Oncology UMC Groningen
Current position July 2010-now: Consultant, Fertility and Gynecology department, University Medical Center Utrecht
Prior positions -1988-1995: Medicine Study, Rijksuniversiteit Groningen
-Aug 1995-Okt 1995: Resident Internal Medicine
De Weezenlanden Hospital, Zwolle
-Okt 1995-May 1997: Resident Gynecology/Obstetrics
De Weezenlanden Hospital, Zwolle
May 1997- Febr 1998: Resident Gynecology/Obstetrics
Martini Hospital, Groningen
Febr 1998- July 2000: Resident and researcher Medical Oncology & Gynaecology Oncology, University Medical Center Groningen
July 2000-July 2006: Traineeship Gynecology and Obstetrics: Isala Klinieken Zwolle, University Medical Center Groningen and Medical Center Leeuwarden.
2006-2010: Consultant, Fertility and Gynecology department, University Medical Center Groningen
2008-July 2010: Consultant and Subspecialisation Fertility and Endocrinology, University Medical Center Groningen
Side Activities
Current Professional memberships
Member of the Dutch Network Gynaecology and Obstetrics (NVOG) >2000
Member European Society Human Reproduction and Endocrinology (ESHRE) >2008
Member Dutch Working party Gynaecological Endoscopy (WGE) (>2012)
Member of the oncologic Mamma Team in the UMC Utrecht (>2011)
Member and secretary (since May 2015) of the Dutch Special Interest Group Fertility preservation (NVOG)
Member of the Special Interest Group Gamete donation (NVOG) >2016
Secretary and vice-president of the Medical Ethical Board of the Department Fertility UMC Utrecht, since April 2015
Member of the Dutch Society of Gender and Health (NVG&G) >2018 (before member of the Alliance Gender and Health)
Chair of the working group Fertility patients in children with cancer in the Prinses Maxima Center. (>June 2018)
Guideline development committees:
- Member of the Dutch Alliance of Gender and Health care (>2012), 2014-2016 making the ‘Kennisagenda Gender and Health’ by estimating knowledge gaps and aims for future research in the field of genderspecific medicine.
-2015-2016 Member of the working group of modern families (NVOG/cie Herijking Ouderschap)
- member of Dutch guideline group: Fertility preservation for women with cancer (2015-2016),
-Initiator and member of the Dutch working group SKION agreement Fertility Preservation for girls and adolescents 0-18 yrs (2016) (gynecologist and pediatric oncologists)
-Modelreglement Embryowet (NVOG and KLEM) Advisory board August 2018
-Member of the working group for development of fertility preservation guidelines in female cancer patients (0-18 years) as part of the IGHG project/PancareLife European project (>2016-2018).
Fellowship and Awards
Child Health Boost grant, sept 2017. 15K euro for the start-up of the EXOTiC project (Exploring the feasibility of EXcellent fertility counseling care for girls with cancer and the safety of Ovarian Tissue Cryopreservation on a national level).
Research team: Annelies Bos, Marry van den Heuvel-Eibrink, Marc Wijnen, Birgitta Versluijs, Simone Broer en Frank Broekmans
The proposed EXOTiC project will be the start of an integral part of the joint clinical and research program on fertility preservation care for children up to 19 years of age in the Princess Máxima Center for Pediatric Oncology and the Department of Reproductive Medicine, UMC Utrecht.
Research Output (17)
What constitutes a reasonable compensation for non-commercial oocyte donors:an analogy with living organ donation and medical research participation
Kool Emy, van der Graaf Rieke, Bos Annelies, Fauser Bartholomeus, Bredenoord Annelien 1 nov 2019, In: Journal of Medical Ethics. 45 , p. 736-741 6 p.
Stakeholders views on the ethical aspects of oocyte banking for third-party assisted reproduction:a qualitative interview study with donors, recipients and professionals
Kool E M, van der Graaf R, Bos A M E, Pieters J J P M, Custers I M, Fauser B C J M, Bredenoord A L 30 mrt 2019, In: Human Reproduction. 34 , p. 842-850 9 p.
Ethics of oocyte banking for third-party assisted reproduction:a systematic review
Kool E M, Bos A M E, van der Graaf R, Fauser B C J M, Bredenoord A L 2018, In: Human Reproduction Update. 24 , p. 615-635 21 p.
Stimulation of the ovaries in women with breast cancer undergoing fertility preservation:Alternative versus standard stimulation protocols; the study protocol of the STIM-trial
Dahhan T., Balkenende E.M., Beerendonk C. C.M., Fleischer K., Stoop D., Bos A. M.E., Lambalk Cornelis B., Schats R, van Golde Ron J T, Schipper I., Louwé L. A., Cantineau A. E.P., Smeenk Jesper M J, Bruin Jacob P, Reddy D N, Kopeika Y., van der Veen F, Wely M., Linn S. C., Goddijn M. 1 okt 2017, In: Contemporary Clinical Trials. 61 , p. 96-100 5 p.
Autonomy and self-esteem of women who donate to an oocyte cryopreservation bank in the Netherlands
Bakker Marjolein R, Maas Joyce, Bekker Marrie H, Bredenoord Annelien L, Fauser Bart C, Bos Annelies M aug 2017, In: Reproductive Biomedicine Online. 35 , p. 225-231
Vruchtbaarheid na kanker verdient meer aandacht
Beerendonk Ina, Bos AME, Witteveen E., Veening Margreet A. 12 jan 2017, In: Medisch Contact. 2 , p. 24-26
Derde Pijlerdag Voortplantingsgeneeskunde, the best of 2 worlds.
Bos AME, Klinkert E.R., Peters Inge, Cantineau A. E.P. 2017, In: Nederlands Tijdschrift voor Obstetrie & Gynaecologie. 130 , p. 64-67 4 p.
Serum AMH levels in healthy women from BRCA1/2 mutated families:are they reduced?
van Tilborg Theodora C, Derks-Smeets Inge A P, Bos Anna M E, Oosterwijk Jan C, van Golde Ron J, de Die-Smulders Christine E, van der Kolk Lizet E, van Zelst-Stams Wendy A G, Velthuizen Maria E, Hoek Annemieke, Eijkemans Marinus J C, Laven Joop S E, Ausems Margreet G E M, Broekmans Frank J M nov 2016, In: Human Reproduction. 31 , p. 2651-2659 9 p.
Do BRCA1/2 mutation carriers have an earlier onset of natural menopause?
van Tilborg Theodora C, Broekmans Frank J, Pijpe Anouk, Schrijver Lieske H, Mooij Thea M, Oosterwijk Jan C, Verhoef Senno, Gómez Garcia Encarna B, van Zelst-Stams Wendy A, Adank Muriel A, van Asperen Christi J, van Doorn Helena C, van Os Theo A, Bos Anna M., Rookus Matti A, Ausems Margreet G aug 2016, In: Menopause. 23 , p. 903-910 8 p.
Patients' and Health Care Providers' Opinions on a Supportive Health App During Breast Cancer Treatment:A Qualitative Evaluation
Young Afat Danny A, van Gils Carla H, Bruinvels David J., van der Pol Carmen C, Witkamp Arjen J, Sijtsema Sieta, Jonasse Yvette, Bijlsma Rhodé M, Ausems Margreet G, Bos Annelies M, van den Bongard Desirée H, Verkooijen Helena M 1 jun 2016, In: JMIR Cancer. 2 , p. e8 8 p.